



**Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization**  
**31 March – 02 April 2020**  
**Virtual Meeting**  
**Agenda**

**Tuesday 31 March 2020**

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
10:00	<b>Closed SAGE meeting</b>	Preparation of the sessions of the day. Other important discussion items.	1h
11:00	<b>Opening – WHO/DDG</b> S. JAKAB. Deputy Director-General.  <b>Welcome – introduction of participants</b>  A. CRAVIOTO. Chair of SAGE.		20 min.
11:20	<b>Global and Regional Reports - Session 1</b>  Report from the Director of IVB. K. O'BRIEN. WHO. 30 min.  Updates from the Regions. 10 min.  Modelling of COVID-19 epidemiology. K. VANDEMAELE. WHO. 20 min.  Update from Gavi. S. BERKLEY. 10 min.  Updates from the Regions- Contd. 20 min.	<b>FOR INFORMATION</b>	1h 30 min.
<b>13:45</b>	<b>Break</b>	<b>Break</b>	<b>15 min.</b>
14:00	<b>Update on COVID-19 vaccine – Session 2</b>  Status of vaccine development. A-M. HENAO RESTREPO. WHO. 15 min.  Discussion: 15 min.	<b>FOR INFORMATION</b>  Update on the pathways for development of a vaccine against COVID-19.	40 min.
14:40	<b>Update on Ebola vaccine - Session 3</b>  Situation update Democratic Republic of the Congo (DRC). A. DIALLO. WHO. 10 min.  Analysis of DRC data in terms of effectiveness of ring vaccination on disease transmission. R. PETO. University of Oxford. 10 min.  Discussion: 10 min.	<b>FOR INFORMATION</b>  Update on the Ebola epidemic in DRC, on vaccine use and safety reports, and other vaccine developments.	30 min.
15:10	<b>Measles outbreak epidemiology and WHO coordination - Session 2</b>  Response to measles outbreaks. K. KRETSINGER. WHO. 25 min.  Ongoing and upcoming measles and rubella policy and strategic work. K. O'BRIEN. 10 min.	<b>FOR DISCUSSION</b>  Target outcomes: 1. SAGE is informed of the current status of measles outbreaks and WHO response efforts.	1h

Discussion: 25 min.	SAGE provides feedback on current WHO plan for upcoming measles rubella strategic work and addressing policy needs.
<b>16:05 End of Day</b>	

**Wednesday 01 April 2020**

10:00	<b>Closed SAGE meeting</b>	Preparation of the sessions of the day. Recap of day 1. Other important discussion items.	1h
11:00	<b>Polio - Session 5</b>  Update from the Global Polio Eradication Initiative. M. ZAFFRAN. WHO. 15 min.  Questions: 5 min.  Update on cVDPV2 epidemiology and overview of the new cVDPV2 outbreak response strategy focusing on tOPV and IPV use. O. MACH. WHO. 15 min.  Questions: 5 min.  Update on nOPV2 development: <ul style="list-style-type: none"> <li>Summary of nOPV2 clinical data. A. BANDYOPADHYAY. BMGF. 15 min.</li> <li>Framework for initial-use of nOPV2 under Emergency Use Listing (EUL). G. MACKLIN. WHO. 15 min.</li> </ul> Discussion: 30 min.  Report from SAGE Polio Working Group including recommendations for regions considering switch to IPV only schedules. I. JANI. SAGE Member. 20 min.  Discussion: 30 min.	<b>FOR DISCUSSION AND DECISION</b>  SAGE will be informed on the current status of the polio eradication program; revised strategies to respond to cVDPV outbreaks; and nOPV2 development.  SAGE will be asked to review and consider for endorsement: <ul style="list-style-type: none"> <li>Policy implications of the new cVDPV2 outbreak response strategy (tOPV and IPV use)</li> <li>Framework for initial use of nOPV2.</li> </ul>	2h 30 min.
13:30	<b>Break</b>	<b>Break</b>	<b>30 min.</b>
14:00	<b>IA2030 Monitoring and Evaluation framework - Session 6</b>  GVAP lessons learned and implications for the IA 2030 ME&A Framework. N. ARORA. SAGE DoV Working Group. 5 min.  Presentation on the aims and principles of IA2030 Monitoring, Evaluation & Action (ME&A) Framework, its development process and the Strategic Priority Goals and Objectives. A. LINDSTRAND. WHO. 15 min.  Possible links of IA2030 ME&A Framework to Governance & Accountability mechanisms. K. O'BRIEN. WHO. 5 min.  Questions to SAGE. A. LINDSTRAND. WHO. 5 min.  Discussion: 30 min.	<b>FOR DISCUSSION</b>  1. Share updates from the IA2030 M&E Task Force, including: <ul style="list-style-type: none"> <li>Aims and principles of IA2030 Monitoring, Evaluation &amp; Action (ME&amp;A) Framework</li> <li>IA2030 ME&amp;A Framework development process</li> <li>Revised IA2030 Strategic Priority Goals and Objectives</li> <li>Possible links of IA2030 ME&amp;A Framework to Governance &amp; Accountability mechanisms</li> <li>How GVAP lessons learned inform development of the IA 2030 ME&amp;A Framework</li> </ul> 2. Receive feedback from SAGE on: <ul style="list-style-type: none"> <li>IA2030 ME&amp;A Framework development process</li> <li>Options for development of IA2030 ME&amp;A Framework indicators and targets</li> </ul>	1h

03 April 2020

		<ul style="list-style-type: none"> <li>Possible links of IA2030 ME&amp;A Framework to Governance &amp; Accountability mechanisms</li> </ul>	
<b>15:00</b>	<b>Break</b>	<b>Break</b>	<b>15 min.</b>
15:15	<b>Global Vaccine Safety Blueprint 2.0 - Session 7</b>	<b>FOR DISCUSSION AND DECISION</b>	1h
	<p>Introduction. K. JOHANSEN. SAGE member. 5 min.</p> <p>Global Vaccine Safety Blueprint 2.0. E. ASTURIAS. Children's Hospital Colorado. 15 min.</p> <p>Discussion: 40 min.</p>	<p>For revision and endorsement of the Global Vaccine Safety Blueprint 2.0</p> <p>Questions to SAGE proposed by GACVS:</p> <ol style="list-style-type: none"> <li>1. What strategic shift could be made to move from GVS1.0 to GVS2.0?</li> <li>2. Are there strategies for identifying resources and mechanisms for finding funds without using those reserved for vaccination?</li> <li>3. What are the recommendations for moving forward, including possible adjustments to the Global Vaccine Safety Initiative?</li> </ol>	
<b>16:15</b>	<b>End of the day</b>		

**Thursday, 02 April 2020**

12:00	<b>Closed SAGE meeting</b>	Recap of day 2. Other important discussion items.	2h
<b>14:00</b>	<b>End of the meeting</b>		